@article{cb93dc9411214ac5aa942eb1b71bce4e,
title = "Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic Leukemia",
abstract = "Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival improvements to the same extent as younger and older patients. We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL) among children (n = 981), AYAs (n = 1218), and older adults (n = 469) who underwent transplantation over 3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did not change over time for older adults. Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type. In this subgroup, there were differences in transplantation practices among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.",
keywords = "Adolescent and young adults, Allogeneic, Hematopoietic cell transplantation, Survival",
author = "Wood, {William A.} and Lee, {Stephanie J.} and Ruta Brazauskas and Zhiwei Wang and Aljurf, {Mahmoud D.} and Ballen, {Karen K.} and Buchbinder, {David K.} and Jason Dehn and Freytes, {Cesar O.} and Lazarus, {Hillard M.} and LeMaistre, {Charles F.} and Paulette Mehta and David Szwajcer and Steven Joffe and Majhail, {Navneet S.}",
note = "Funding Information: Financial disclosure: CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, the National Heart, Lung and Blood Institute , and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from National Heart, Lung and Blood Institute and National Cancer Institute; a contract HHSH234200637015C with Health Resources and Services Administration; grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Inc. , Amgen, Inc. , and Angioblast; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US government. ",
year = "2014",
month = jun,
doi = "10.1016/j.bbmt.2014.02.021",
language = "English (US)",
volume = "20",
pages = "829--836",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",
}